Cost-effectiveness of sigmoid resection with primary anastomosis or end colostomy for perforated diverticulitis: an analysis of the randomized Ladies trial

D. P. V. Lambrichts1,2, S. van Dieren2, W. A. Bemelman2 and J. F. Lange1,3

Departments of Surgery, 1Erasmus University Medical Centre, Rotterdam, 2Amsterdam University Medical Centre, AMC, Amsterdam, and 3Ijsselland Hospital, Capelle aan den IJssel, the Netherlands

Correspondence to: Mr D. P. V. Lambrichts, Department of Surgery, Erasmus University Medical Centre, Room Ee-173, PO Box 2040, 3000 CA Rotterdam, the Netherlands (e-mail: d.lambrichts@erasmusmc.nl)

Background: Several studies have been published favouring sigmoidectomy with primary anastomosis over Hartmann’s procedure for perforated diverticulitis with purulent or faecal peritonitis (Hinchey grade III or IV), but cost-related outcomes were rarely reported. The present study aimed to evaluate costs and cost-effectiveness within the DIVA arm of the Ladies trial.

Methods: This was a cost-effectiveness analysis of the DIVA arm of the multicentre randomized Ladies trial, comparing primary anastomosis over Hartmann’s procedure for Hinchey grade III or IV diverticulitis. During 12-month follow-up, data on resource use, indirect costs (Short Form Health and Labour Questionnaire) and quality of life (EuroQol Five Dimensions) were collected prospectively, and analysed according to the modified intention-to-treat principle. Main outcomes were incremental cost-effectiveness (ICER) and cost–utility (ICUR) ratios, expressed as the ratio of incremental costs and the incremental probability of being stoma-free or incremental quality-adjusted life-years respectively.

Results: Overall, 130 patients were included, of whom 64 were allocated to primary anastomosis (46 and 18 with Hinchey III and IV disease respectively) and 66 to Hartmann’s procedure (46 and 20 respectively). Overall mean costs per patient were lower for primary anastomosis (€20544, 95 per cent c.i. 19569 to 21519) than Hartmann’s procedure (€28670, 26636 to 30704), with a mean difference of €–8126 (–14660 to –1592). The ICER was €–39094 (95 per cent bias-corrected and accelerated (BCa) c.i. –1213 to –116), indicating primary anastomosis to be more cost-effective. The ICUR was €–101435 (BCa c.i. –1113264 to 251840).

Conclusion: Primary anastomosis is more cost-effective than Hartmann’s procedure for perforated diverticulitis with purulent or faecal peritonitis.

Introduction

Acute diverticulitis is a common diagnosis in developed countries that is associated with considerable healthcare costs1–5. The incidence of perforated diverticulitis with purulent or faecal peritonitis (Hinchey grade III or IV) is increasing, emphasizing the need for cost-effective emergency surgical management6,7.

In recent years, results have been published favouring sigmoidectomy with primary anastomosis (PA) over Hartmann’s procedure (HP) for the treatment of Hinchey III and IV diverticulitis8. Benefits of PA comprise lower short-term morbidity rates after index and reversal procedures, as well as a higher rate of stoma-free survival, shorter time to stoma reversal and shorter postreversal hospital stay8–11. Although these outcomes might reduce associated costs, studies comparing the two treatment strategies in terms of related costs and cost-effectiveness are scarce. Therefore, a cost-effectiveness analysis was undertaken comparing PA (with or without defunctioning ileostomy) with HP in patients treated in the DIVA arm of the Ladies trial11,12.

Methods

This cost-effectiveness analysis was conducted within the DIVA arm of the Ladies trial. The study protocol,
including details of cost analyses and clinical outcomes, has been reported previously\textsuperscript{11,12}. In summary, the Ladies trial was an international, multicentre, parallel-group, randomized, open-label superiority trial of the surgical management of perforated diverticulitis. The aim of the DIVA arm was to compare HP and PA (with or without defunctioning ileostomy) as treatment for Hinchey III or IV diverticulitis. After diagnostic laparoscopy, patients were assigned randomly to HP or PA in a 1:1 ratio. Patients with dementia, a history of sigmoidectomy or pelvic radiotherapy, chronic steroid treatment (at least 20 mg daily) or preoperative shock requiring inotropic support were excluded. The primary endpoint of the DIVA arm was 12-month stoma-free survival and secondary outcomes (such as morbidity and readmissions) were also recorded. The study was registered at trialregister.nl (NTR2037) and ClinicalTrials.gov (NCT01317485), and designed in accordance with the Declaration of Helsinki and good clinical practice guidelines. The study protocol was approved by the ethical review board, and written informed consent was obtained from all patients before randomization. The CHEERS guidelines and checklist\textsuperscript{13} were used as guidance for the present cost-effectiveness analysis.

**Economic evaluation**

The present analysis aimed to assess the cost-effectiveness and cost–utility of HP compared with PA during the first 12 months after the index procedure, and included both direct and indirect costs (medical and non-medical). The economic evaluation was performed from a societal perspective, and in accordance with the guidelines for health economic analyses published by the Dutch National Health Care Institute\textsuperscript{14}.

**Resource use**

Data on resource use were collected prospectively through clinical record forms and study questionnaires completed 1, 3, 6, 9 and 12 months after the index procedure. Direct medical costs were those related to index and stoma reversal surgery and related admissions (such as ward and ICU stay), reinterventions (acute relaparotomy or percutaneous drainage), additional diagnostic imaging (X-ray, ultrasound imaging, CT), readmissions, stoma care, emergency department visits, and outpatient consultation visits with the surgeon, gastroenterologist, general practitioner or company physician. Costs of the index procedure actually performed were used and did not include the cost of the study protocol-based diagnostic laparoscopy. Costs associated with home and informal care and travel expenses were considered as direct non-medical costs. Indirect non-medical costs resulting from work absence or decreased productivity were determined by use of the Short Form Health and Labour Questionnaire (SF-HLQ)\textsuperscript{15}. To estimate loss of productivity, the friction costs method was used with age-adjusted mean daily wages derived from the Dutch National Health Care Institute guideline\textsuperscript{14}. Total costs per patient were calculated by multiplying resources used by associated unit costs.

**Quality-adjusted life-years**

Health-related quality of life (QoL) and quality-adjusted life-years (QALYs) were derived from the EuroQol Five Dimensions three-level questionnaire (EQ-5D-3 L\textsuperscript{TM}; EuroQol Group, Rotterdam, the Netherlands) at 2 and 4 weeks, 3, 6 and 12 months after the index procedure. Outcomes were scored from 0 to 1 according to the Dutch EQ-5D\textsuperscript{TM} tariff, where 1 is considered to represent optimal QoL.

**Unit costs**

Unit costs were calculated according to the methods described by Vennix and colleagues\textsuperscript{16}, and were estimated based on top-down cost calculations from the hospital costs ledger of the Amsterdam University Medical Centre and Dutch guideline on unit costing in healthcare\textsuperscript{17}. Moreover, bottom-up cost calculations for laparoscopic and open sigmoidectomy with and without PA were performed, including costs of instruments (reusable and disposable), and costs of personnel and overheads per time unit. As the index procedures and Hartmann’s reversal procedures could be open or laparoscopic, mean costs were calculated taking the ratio of these different possible procedures into account. Costs were calculated in euros, adjusted to 2018 by the Dutch consumer price index.

**Statistical analysis**

Depending on data distribution, continuous variables are presented as median (i.q.r.) or mean(s.d.). Categorical variables are shown as numbers with percentages. Patients were analysed according to the modified intention-to-treat principle, with costs calculated based on the index procedure actually performed. The intention-to-treat approach was deemed modified owing to the exclusion of three patients shortly after randomization who were found...
to have alternative diagnoses\textsuperscript{11}. The bias-corrected and accelerated (BCa) bootstrapping method (1000 samples) was used to calculate 95 per cent confidence intervals\textsuperscript{18}. Missing data on EQ-5D™ values and indirect costs were imputed by means of multiple imputation, taking into account age, sex, Hinchey grade, randomization and direct costs. Imputed data were pooled according to Rubin’s rule\textsuperscript{19}. To determine the robustness of the calculated costs, sensitivity analyses were performed by varying unit costs of resources used (direct medical costs). Incremental cost-effectiveness (ICER) and cost–utility (ICUR) ratios were calculated as the mean difference between treatment groups in total costs per patient divided by the mean difference in probability of being stoma-free and mean difference in QALYs respectively. Cost-effectiveness planes and acceptability curves were derived. Analyses were performed using SPSS® version 24.0 (IBM, Armonk, New York, USA) and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

Between 1 July 2010 and 22 February 2013, and between 9 June 2013 and 6 June 2016, patients could be included in the DIVA arm of the Ladies trial. Trial inclusion was temporarily paused, owing to the early termination of the LOLA arm of the study. Eventually, a total of 130 patients were included according to a modified intention-to-treat principle, of whom 66 were analysed in the HP group and 64 in the PA group. One patient in the PA group was lost to follow-up after 30 days (Fig. S1, supporting information). All patients were included in the present cost evaluation. Baseline and operative characteristics are summarized in Table 1. Full trial details and outcomes have been published previously\textsuperscript{11}. Response rates to the SF-HLQ questionnaires are documented in Table S1 (supporting information).

### Costs and resource use

A summary of unit costs of major resources is provided in Table 2, with full details in Table S2 (supporting information). Resource use and calculated costs are shown in Table 3. Stoma-related costs were significantly higher in the HP group (€8372, 95 per cent c.i. 7316 to 9429) than in the PA group (€4382, 3481 to 5284), with a mean difference of €–3990 (–5370 to –2611). Overall total costs were €1892206 for the HP group and €1314798 for the PA group. Mean costs per patient were €28 670 (26 636 to 30 704) and €20 544 (19 569 to 21 519) respectively. This amounted to a mean difference in costs of €–8126 (–14 660 to –1592) in favour of PA.

### Cost-effectiveness and cost–utility

The mean probability of being stoma-free at end of the 12-month follow-up was 86 (95 per cent c.i. 74 to 93)
Table 3 Resource use and costs

|                               | Hartmann’s procedure (n = 66) | Primary anastomosis (n = 64) |
|-------------------------------|------------------------------|------------------------------|
|                               | Unit                         | Total units | Total costs (€) | Unit | Total units | Total costs (€) |
| Index admission               |                              |             |                 |      |             |                 |
| Hartmann’s procedure          | Procedure                    | 65          | 211 083         | 7    | 22 732      |
| Primary anastomosis           | Procedure                    | 1           | 39 114          | 56   | 219 181     |
| Laparoscopic lavage           | Procedure                    | 0           | 0               | 1    | 2346        |
| Surgical ward                 | Day                          | 733         | 307 076         | 591  | 247 588     |
| Intensive care unit           | Day                          | 197         | 410 611         | 87   | 181 336     |
| Additional imaging            | Test                         | 264         | 31 039          | 159  | 21 448      |
| Subtotal                      |                              | 963 723     | 694 630         |
| Mean subtotal per patient     | 14 602 (8514, 20 689)        | 10 854 (9126 to 12 581)    |
| Mean difference in subtotal   | −3748 (−10 101, 2604)        |               |
| Readmissions and reinterventions |                          |             |                 |      |             |                 |
| Acute reinterventions         | Procedure                    | 18          | 31 064          | 12   | 28 154      |
| Elective reinterventions      | Procedure                    | 4           | 52 18           | 1    | 13 056      |
| Readmission to surgical ward  | Day                          | 172         | 72 056          | 142  | 59 488      |
| Readmission intensive care unit | Day                        | 0           | 0               | 0    | 0           |
| Subtotal                      |                              | 108 339     | 88 946          |
| Mean subtotal per patient     | 1641 (826, 2657)             | 1390 (677, 2102)           |
| Mean difference in subtotal   | −252 (−1488 to 984)          |               |
| Stoma-related costs           |                              |             |                 |      |             |                 |
| Stoma care                    | Day                          | 13 118      | 245 965         | 8288 | 104 737     |
| Reversal surgery              | Procedure                    | 45          | 183 915         | 38   | 106 612     |
| Reversal admission (surgical ward + ICU) | Day          | 277         | 122 705         | 165  | 69 123      |
| Subtotal                      |                              | 552 584     | 280 473         |
| Mean subtotal per patient     | 8372 (7316, 9429)            | 4382 (3481, 5284)          |
| Mean difference in subtotal   | −3990 (−5370, −2611)         |               |
| Other costs                   |                              |             |                 |      |             |                 |
| Imaging                       | Test                         | 64          | 9282            | 38   | 4811        |
| Consultations and travel expenses | Visit                       | 349         | 30 038          | 295  | 26 423      |
| Total direct medical costs    |                              | 1 663 966   | 1 095 283       |
| Indirect non-medical costs    |                              | 228 240     | 219 515         |
| Total costs (12 months)       |                              | 1 892 206   | 1 314 798       |
| Mean cost per patient         | 28 670 (26 636, 30 704)      | 20 544 (19 569, 21 519)    |
| Mean difference in costs      | −8126 (−14 660, −1592)       |               |

Values in parentheses are 95 per cent confidence intervals. Mean costs are shown, indexed for 2018. Smaller cost groups (such as hospital and general practitioner visits) are included in (sub)total costs.

per cent for the PA group and 65 (53 to 75) for the HP group, with a significant mean difference of 21 (7 to 36) per cent. Fig. 1 shows a cost-effectiveness plane, indicating the relationship between incremental costs and the incremental probability of being stoma-free and alive. The ICER was €−39 094 (95 per cent BCa c.i. −12 13 to −116), indicating that PA was more cost-effective than HP. The associated willingness-to-pay curve is shown in Fig. S2 (supporting information).

The mean value of QALYs during the 12-month follow-up was 0.72 (95 per cent c.i. 0.69 to 0.76) in the PA group, compared with 0.64 (0.60 to 0.68) in the HP group. The mean difference in QALYs was 0.08 (−0.03 to 0.19), which was not statistically significant. The ICUR was €−101 435 (95 per cent BCa c.i. −1 113 264 to 251 840). A cost–utility plane and willingness-to-pay curve are shown in Fig. 2 and Fig. S3 (supporting information) respectively.
Black dot indicates the point estimate upon which the 1000 bootstrap samples are based.

**Table 4** Sensitivity analyses of medical costs

|                          | Hartmann’s procedure (€) | Primary anastomosis (€) | Cost difference (€) |
|--------------------------|--------------------------|-------------------------|---------------------|
| **Total medical costs (base-case analysis)** | 25 212 (21 251, 34 132) | 17 114 (15 297, 19 636) | –8098 (–17 016, –3550) |
| **Index surgery**       |                          |                         |                     |
| –50%                    | 23 583 (19 603, 32 482) | 15 206 (13 398, 17 789) | –8377 (–17 214, –3818) |
| +50%                    | 26 840 (22 847, 37 381) | 19 022 (16 978, 21 455) | –7818 (–18 129, –3269) |
| **Hospital stay (ward, ICU)** |                          |                         |                     |
| –20%                    | 23 036 (19 258, 30 896) | 15 773 (14 139, 17 939) | –7263 (–14 878, –2910) |
| +20%                    | 27 386 (22 398, 39 156) | 18 454 (16 284, 21 358) | –8932 (–19 534, –3261) |
| **Stoma–associated costs** |                          |                         |                     |
| –20%                    | 23 537 (19 566, 33 672) | 16 237 (14 598, 18 812) | –7300 (–16 843, –2507) |
| +20%                    | 26 886 (22 880, 35 540) | 17 990 (16 064, 20 586) | –8896 (–17 734, –4320) |
| **Acute or elective reintervention** |                          |                         |                     |
| –20%                    | 25 102 (21 174, 35 659) | 17 022 (15 370, 19 443) | –8079 (–18 375, –3742) |
| +20%                    | 25 321 (21 399, 36 105) | 17 206 (15 499, 19 746) | –8116 (–18 526, –3742) |

Values in parentheses are 95 per cent confidence intervals.

**Sensitivity analyses**

*Table 4* shows the results of sensitivity analyses, in which unit costs for specified cost groups were increased and decreased by 20 or 50 per cent, while those for other cost groups were not changed. Overall, these results demonstrated that PA was associated with lower costs, with cost differences ranging from €–7263 to €–8932.

**Discussion**

Admission rates for diverticulitis have increased over the past few decades, and the incidence of perforated disease, for which surgery is often needed, has risen. In a retrospective study, overall expenses were between 74 and 229 per cent higher for HP than PA. More recently, in-hospital costs within an RCT were found to be higher for HP, but this was not statistically significant. The present
study differed from previous analyses by capturing all costs prospectively, including indirect non-medical and other resource expenses (such as those related to readmissions or outpatient department visits) over the full 12-month follow-up. It showed that PA was more cost-effective in the first postoperative year and in terms of the probability of being stoma-free. Advantages of PA derive from a shorter time to, and less morbidity after, stoma reversal, and a shorter hospital stay, which are likely to reduce costs. Indeed, a large difference in absolute stoma-related costs was identified in favour of PA. This is in line with a cost-effectiveness analysis of the LOLA arm of the Ladies trial, in which stoma-related costs were higher for resection than laparoscopic lavage for Hinchey III diverticulitis, and the economic analysis of the related DILALA (Diver- ticulitis – LAparoscopic LAverage versus resection (Hartmann’s procedure) for acute diverticulitis with peritonitis) study.

In terms of generalizability, some aspects are of importance to consider when interpreting the present outcomes. The majority of patients included in the Ladies trial were Dutch, and unit costs and subsequent calculations are based on that healthcare system. The results should be interpreted within the context of the inclusion and exclusion criteria that applied to the DIVA arm. Therefore, strictly speaking, the present outcomes apply only to haemodynamically stable, immunocompetent patients aged less than 85 years. Enrolment was terminated early because of slow accrual. Although not uncommon for RCTs in the emergency setting, early termination may limit the sample size and statistical power. The study was not specifically powered to show differences in cost-associated or patient-reported outcomes. Hence, it was decided not to differentiate between Hinchey III and IV diverticulitis in the present study, as this would have further reduced group sizes. In spite of the sample size, significant differences in overall mean costs per patient were identified, and their robustness was demonstrated in sensitivity analyses. Another limitation was the response rate to the questionnaires sent out during follow-up, which ranged from 47 to 64 per cent. Multiple imputation techniques were used to handle missing data and to decrease the influence of potential attrition bias.

This study has several strengths, including the setting of a multicentre randomized trial with cost data collected prospectively from a societal perspective, and indirect non-medical costs (such as absence from work and productivity losses) taken into account. These factors are relevant to consider as the disease is increasingly being seen in younger patients of working age. The assessment of unit costs came from the hospital ledger and Dutch costing manual, rather than being derived from diagnosis-related group data, to better reflect clinical practice at a more individual level.
In general, the treatment of diverticulitis has shifted towards less aggressive approaches, which might also have beneficial effects on associated costs\(^1\). The avoidance of antibiotics for uncomplicated diverticulitis has been proven to be safe in both the short and long term\(^2\)\(^\text{-}\)\(^5\). The role of antibiotics for uncomplicated diverticulitis has been proven to be avoided if possible and that PA is preferred\(^6\)\(^\text{-}\)\(^8\). The evidence shows that HP for perforated diverticulitis should be avoided if possible and that PA is preferred\(^9\)\(^\text{-}\)\(^11\). The present cost-effectiveness analysis has provided a health economic argument for use of PA over HP for perforated diverticulitis.

**Collaborators**

Members of the Ladies trial who collaborated in this study: Study design: J. Vermeulen (Department of Surgery, Maassstad Hospital, Rotterdam); W. C. Hop (Department of Epidemiology, Erasmus University Medical Centre, Rotterdam); B. C. Opmeer (Clinical Research Unit, Amsterdam University Medical Centre, AMC, Amsterdam); J. B. Reitsma (Julius Centre for Health Sciences, University Medical Centre Utrecht, Utrecht). Randomization management: R. A. Scholte, E. W. H. Walmann (Clinical Research Unit, Amsterdam University Medical Centre, AMC, Amsterdam). Data Safety Monitoring Board: D. A. Legemate (Department of Surgery, Amsterdam University Medical Centre, AMC, Amsterdam); J. F. Bartelsman (Department of Gastroenterology, Amsterdam University Medical Centre, AMC, Amsterdam); D. W. Meijer (Department of Surgery, Amsterdam University Medical Centre, VUmc, Amsterdam); J. B. Reitsma (Julius Centre for Health Sciences, University Medical Centre Utrecht, Utrecht). Investigators and participating surgeons/residents of the DIVA arm; Netherlands: W. A. Bemelman, S. Vennix, G. D. Musters, H. A. Swank, C. Ünlü, A. B. Kluit, Y. El-Massoudi, R. J. C. L. M. Vuylsteke, P. J. Tanis, R. Matthijsen, S. W. Polle, S. M. Lagarde, S. S. Gisbertz, O. Wijers, J. D. W. van der Bilt, M. A. Boermeester, R. Blom, J. A. H. Gooszen, M. H. F. Schreinemacher, T. van der Zande, M. M. N. Leeuwenburgh (Department of Surgery, University Medical Centre, AMC, Amsterdam); J. A. van der Hoeven, S. A. L. Bartels, W. L. E. M. Hesp, L. Koet (Department of Surgery, Albert Schweitzer Hospital, Dordrecht); R. M. P. H. Croella, G. P. van der Schelling, E. van Dessel, M. L. P. van Zeeland, M. M. A. Lensvelt, H. Nijhof, S. Verest, M. Buijs, J. H. Wijsman (Department of Surgery, Amphia Hospital, Breda); L. P. S. Stassen, M. Klinkert, M. F. G. de Maat, G. Sellenraad (Department of Surgery, Academic Hospital Maastricht, Maastricht); J. F. Lange, I. M. Mulder, J. Jeekel, G. J. Kleinrensink, T. Tha-In, W. N. Nijboer (Department of Surgery, Erasmus University Medical Centre, Rotterdam); M. J. Boom, P. C. M. Verbeek (Department of Surgery, Flevo Hospital, Almere); P. M. Kruyt, C. Sietse, M. W. J. Stommel (Department of Surgery, Gelderse Vallei Hospital, Ede); W. H. Steup, P. J. van Huijstee, J. W. S. Merkus, D. Eefting, J. S. D. Mieog (Department of Surgery, Haga Hospital, The Hague); E. G. J. M. Pierik, D. van Geldere, G. A. Patijn, M. de Vries, M. Boskamp (Department of Surgery, Isala Hospital, Zwolle); H. B. A. C. Stockmann, Q. A. J. Eijshouts, A. Bentohami, T. S. Bijlsma, N. de Korte, D. Nio, H. Rijna, J. Luttkihold, M. H. van Gool, J. F. Fekeks, G. J. M. Akkersdijk, G. Heuff, E. H. Jutte, B. A. Kortmann, J. M. Werkman, W. Laméris, L. Rietbergen, P. Frankenmolen (Department of Surgery, Spaarne Gasthuis, Haarlem); E. C. J. Consten, W. A. Draaisma, M. A. W. Stam, M. S. Verweij (Department of Surgery, Meander Medical Centre, Amersfoort); M. F. Gerhards, B. A. van Wagensveld, T. M. Karsten, H. Rijna, L. C. de Nes, S. Fortuin, S. M. De Castro, A. Doeksen, M. P. Simons, G. I. Koffeman, E. P. Steller, J. B. Tuyman, P. Boele van Hensbroek, M. Mok, S. R. van Diepen (Department of Surgery, OLVG, Amsterdam); A. G. M. Hoofwijk, H. J. Belgers, K. W. E. Hulsewé, J. Melenhorst, J. H. M. B. Stoot, S. Fransen, M. N. Soef, J. van Bastelaar, Y. L. J. Vissers, T. P. D. Douchy, C. E. Christiaansen, R. Smeenk, A. M. Pijnenburg, V. Tanaydin, H. T. C. Veger, S. H. E. M. Clermonts, M. Al-Täher (Department of Surgery, Zuyderland Medical Centre, Sittard-Geleen); E. J. R. de Graaf, A. G. Menon, M. Vermaas (Department of Surgery, IJsselland Hospital, Capelle aan den IJssel); H. A. Cense, E. Jutte (Department of Surgery, Rode Kruis Hospital, Beverwijk); T. M. Karsten, M. Vermaas (Department of Surgery, Reinder de Graaf Hospital, Delft); M. J. Wiezer, A. B. Smits (Department of Surgery, St Antonius Hospital, Nieuwegein); A. A. W. van Geloven, M. Westerterp, H. A. Marsman, E. R. Hendriks, O. van Ruler, E. J. C. Vriens, J. M. Vogten, C. C. van Rossem, D. Ohanes, E. Tanis, J. van Grinsven (Department of Surgery, Tergooi Hospital, Hilversum); J. K. Maring, J. Heisterkamp (Department of Surgery, Elisabeth-TweeSteden Hospital, Tilburg); W. M. U. van Grevenstein, M. R. Vriens, M. G. H. Besselink, I. H. M. Borel Rinkes, I. Q. Molenaar (Department of Surgery, University Medical Centre, Utrecht); M. J. P. M. Govaert, J. A. J. Joosten, V. Jongkind, G. M. P. Diepenhorst, M. C. Boute, M. Smeenge, K. Nielsen, J. J. Harlaar (Department of Surgery, Dijklander Hospital, Hoon).
Daams, E. van Haren, G. A. P. Nieuwenhuijzen, G. J. Lauret, I. T. A. Pereboom, R. A. Stokmans (Department of Surgery, Catharina Hospital, Eindhoven); J. L. M. Konsten (Department of Surgery, VieCuri Hospital, Venlo); Italy: A. Birindelli, S. Di Saverio, E. Bianchi, S. Pellegrini (Department of Surgery, Maggiore Hospital, Bologna); F. Catena (Department of Surgery, Maggiore Hospital, Parma); Belgium: A. J. L D’Hoore, I. Terrasson, A. Wolthuis, A. de Buck van Overstraeten, S. Nijs (Department of Surgery, University Hospital, Leuven).

Acknowledgements

The authors thank all patients who were willing to participate in this trial, and the collaborators in the DIVA arm of the Ladies trial (listed above). The Ladies trial is part of a national consortium: the Dutch Diverticular Disease (3D) Collaborative Study group. The Ladies trial was funded by a grant from the Netherlands Organization for Health Research and Development (ZonMw 171002213). The authors thank all patients who were willing to participate in the study.

Disclosure: The authors declare no conflict of interest.

References

1 Morris CR, Harvey IM, Stebbings WS, Hart AR. Incidence of perforated diverticulitis and risk factors for death in a UK population. Br J Surg 2008; 95: 876–881.
2 Li D, Baxter NN, McLeod RS, Moineddin R, Wilton AS, Nathens AB. Evolving practice patterns in the management of acute colonic diverticulitis: a population-based analysis. Dis Colon Rectum 2014; 57: 1397–1405.
3 Delvaux M. Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. Aliment Pharmacol Ther 2003; 18: 71–74.
4 Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2018; 156: 254–272.
5 Sköldberg F, Granlund J, Discacciati A, Hjern F, Schmidt PT, Olén O. Incidence and lifetime risk of hospitalization and surgery for diverticular disease. Br J Surg 2019; 106: 930–939.
6 Jamal Talabani A, Lydersen S, Endreseth BH, Edna TH. Major increase in admission- and incidence rates of acute colonic diverticulitis. Int J Colorectal Dis 2014; 29: 937–945.
7 Binda GA, Mataloni F, Bruzzone M, Carabotti M, Crocchi R, Nascimbéni R et al. Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Tech Coloproctol 2018; 22: 597–604.
8 Gachabayov M, Oberkofler CE, Tuch JJ, Hahnloser D, Bergamaschi R. Resection with primary anastomosis vs nonrestorative resection for perforated diverticulitis with peritonitis: a systematic review and meta-analysis. Colorectal Dis 2018; 20: 753–770.
9 Bridoux V, Regimbeau JM, Ouaisi M, Mathonnet M, Mauvais F, Houivet E et al. Hartmann's procedure or primary anastomosis for generalized peritonitis due to perforated diverticulitis: a prospective multicenter randomized trial (DIVERTI). J Am Coll Surg 2017; 225: 798–805.
10 Oberkofler CE, Rickenbacher A, Raptis DA, Lehmann K, Villiger P, Buchli C et al. A multicenter randomized clinical trial of primary anastomosis or Hartmann's procedure for perforated left colonic diverticulitis with purulent or fecal peritonitis. Ann Surg 2012; 256: 819–827.
11 Lambrichts DPV, Vennix S, Musters GD, Mulder IM, Swank HA, Hoofwijk AGM et al. Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial. Lancet Gastroenterol Hepatol 2019; 4: 599–610.
12 Swank HA, Vermeulen J, Lange JF, Mulder IM, van der Hoeven JA, Stassen LP et al. The ladies trial: laparoscopic peritoneal lavage or resection for purulent peritonitis and Hartmann's procedure or resection with primary anastomosis for purulent or faecal peritonitis in perforated diverticulitis (NTR2037). BMC Surg 2010; 10: 29.
13 Huseurea D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al.; CHEERS Task Force. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health 2013; 16: 5.
14 Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Swan Tán SK. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Institute for Medical Technology Assessment, Erasmus Universiteit: Rotterdam, 2018.
15 Van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FFH. Labor and health status in economic evaluation of health care: the Health and Labor Questionnaire. Int J Technol Assessment Health Care 1996; 12: 405–415.
16 Vennix S, Van Dieren S, Oppmeur BC, Lange JF, Remelman WA. Cost analysis of laparoscopic lavage compared with sigmoid resection for perforated diverticulitis in the Ladies trial. Br J Surg 2017; 104: 62–68.
17 Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan SS. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. ‘Van goede zorg verzekerd’. Bijlage 1: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg, 2016. https://www.zorginstituutnederland.nl/binaries/zinl/documented/pubicatie/201602/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/Richtlijn%20voor%20het%20uitvoeren%20van%20economische%20evaluaties%20in%20de%20gezondheidszorg.pdf [accessed 1 July 2019].
18 Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219–3236.
Barnard J, Rubin DB. Miscellanea. Small-sample degrees of freedom with multiple imputation. Biometrika 1999; 86: 948–955.

Broad JB, Wu Z, Xie S, Bissett IP, Connolly MJ. Diverticular disease epidemiology: acute hospitalisations are growing fastest in young men. Tech Coloproctol 2019; 23: 713–721.

Nguyen GC, Sam J, Anand N. Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States. World J Gastroenterol 2011; 17: 1600–1605.

Etzioni DA, Mack TM, Beart RW Jr, Kaiser AM. Diverticulitis in the United States: 1998–2005: changing patterns of disease and treatment. Ann Surg 2009; 249: 210–217.

Bharucha AE, Parthasarathy G, Ditah I, Fletcher JG, Ewelukwa O, Pendlimari R et al. Temporal trends in the incidence and natural history of diverticulitis: a population-based study. Am J Gastroenterol 2015; 110: 1589–1596.

Humes DJ, Solaymani-Dodaran M, Fleming KM, Simpson J, Spiller RC, West J. A population-based study of perforative diverticular disease incidence and associated mortality. Gastroenterology 2009; 136: 1198–1205.

Mäkelä J, Kiviniemi H, Laitinen S. Prevalence of perforated diverticulitis with purulent or fecal peritonitis. Br J Surg 2016; 103: 1539–1547.

Schandelmaier S, Von Elm E, You JJ, Blümle A, Tomonaga Y, Lamontagne F et al. Premature discontinuation of randomized trials in critical and emergency care: a retrospective cohort study. Crit Care Med 2016; 44: 130–137.

Biondo S. The diminishing role of surgery for acute diverticulitis. Br J Surg 2019; 106: 308–309.

Daniels L, Ünlü Ç, De Korte N, Van Dieren S, Stockmann HB, Vrouenraets BC et al. Randomized clinical trial of observational versus antibiotic treatment for the first episode of CT-proven uncomplicated acute diverticulitis. Br J Surg 2017; 104: 52–61.

Chabok A, Pahlman L, Hjern F, Haapaniemi S, Smedh K; AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg 2012; 99: 532–539.

van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. Br J Surg 2020; https://doi.org/10.1002/bjs.11465 [Epub ahead of print].

Isacson D, Smedh K, Nikberg M, Chabok A. Long-term follow-up of the AVOD randomized trial of antibiotic avoidance in uncomplicated diverticulitis. Br J Surg 2019; 106: 1542–1548.

Lambrichts DPV, Bolkenstein HE, van der Does D, Dieleman D, Crolla R, Dekker JWT et al. Multicentre study of non-surgical management of diverticulitis with abscess formation. Br J Surg 2019; 106: 458–466.

Mali J, Mentula P, Leppäniemi A, Sallinen V. Determinants of treatment and outcomes of diverticular abscesses. World J Emerg Surg 2019; 14: 31.

You K, Bendil R, Taut C, Sullivan R, Gachabayov M, Bergamaschi R et al. Randomized clinical trial of elective resection versus observation in diverticulitis with extraluminal air or abscess initially managed conservatively. Br J Surg 2018; 105: 971–979.

Aquina CT, Becerra AZ, Xu Z, Justiniano CF, Noyes K, Monson JRT et al. Population-based study of outcomes following an initial acute diverticular abscess. Br J Surg 2019; 106: 467–476.

Supporting information
Additional supporting information can be found online in the Supporting Information section at the end of the article.